Business
Data at 2026 Boswick Burn & Wound Symposium highlight first integrated use of AVITA Medical technologies
First surgeon-reported case using RECELL®, PermeaDerm®, and Cohealyx™ together in a single care pathwayNew clinical and tissue-level data on PermeaDerm and Cohealyx highlight wound bed preparation and readiness for closureRECELL analyses show consistent trends in healing, reduced complications, and shorter hospital stays across studies and real-world registry data VALENCIA, Calif., Jan. 25, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound
About this update from Avita Medical, Inc.
[{"type":"image","alt":"AVITA Medical","displaySize":"","headline":null,"caption":"AVITA Medical","className":"","disableSlideshowImg":false,"size":{"original":{"width":96,"height":115,"url":"https://media.zenfs.com/en/globenewswire.com/dfd8c445a107185ef69e74538692859e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ejDr4RdwXqFCjMdbUOz.Ig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTExMDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/dfd8c445a107185ef69e74538692859e","width":96,"height":115}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"First surgeon-reported case using RECELL®, PermeaDerm®, and Cohealyx™ together in a single care pathway","length":103,"tagName":"p"}]},{"val":[{"type":"text","content":"New clinical and tissue-level data on PermeaDerm and Cohealyx highlight wound bed preparation and readiness for closure","length":119,"tagName":"p"}]},{"val":[{"type":"text","content":"RECELL analyses show consistent trends in healing, reduced complications, and shorter hospital stays across studies and real-world registry data","length":144,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":366,"olType":false},{"type":"text","content":"VALENCIA, Calif., Jan. 25, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced data from 19 scientific abstracts, including 14 podium presentations, at the 2026 Boswick Burn & Wound Symposium. The presentations include the first surgeon-reported integrated use of all three AVITA Medical technologies – RECELL, PermeaDerm, and Cohealyx – in individual patient cases, as well as clinical and tissue-level findings from separate studies evaluating PermeaDerm and Cohealyx.","length":594,"tagName":"p"},{"type":"text","content":"Additional presentations at the meeting build on AVITA Medical’s established RECELL evidence base, offering synthesis and real-world insight across comparative studies, registries, and older compromised patient populations. Together, the data illustrate how surgeons are using RECELL to improve healing, reduce complications, and shorten hospital stays in burn and complex wound care.","length":384,"tagName":"p"},{"type":"text","content":"First Surgeon-Reported Integrated Use of All Three AVITA Medical Technologies","length":77,"tagName":"p"},{"typ...